Company intelligence / Profile preview
RS BioTherapeutics
Cumberland, Maryland, United Statesrsbiotherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
RSBT-001 has demonstrated positive anti-inflammatory and anti-fibrotic effects in human lung tissue studies, showing statistically significant reduction of key inflammatory biomarkers and mediators of fibrosis in human precision cut lung slices (PCLuS)[2]
- Therapeutic areas
- PulmonologyCardiovascularInfectious Diseases
- Modalities
- Semi-synthetic cannabidiolic acid complex (RSBT-001)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on RS BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RS BioTherapeutics.